Important Notice for Neumora Therapeutics Shareholders Before April 7, 2025

Important Notice for Shareholders of Neumora Therapeutics, Inc.

On April 3, 2025, The Gross Law Firm announced a significant advisory for shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). If you acquired shares of Neumora during a specified class period, it's crucial to reach out to the law firm by April 7, 2025. This date marks not just a deadline, but also an opportunity for shareholders to explore their rights regarding potential claims stemming from the company's actions.

The firm is reaching out specifically to those who purchased shares of Neumora from around September 15, 2023, onward. Shareholders intrigued by the idea of pursuing justice for stock losses are encouraged to contact The Gross Law Firm regarding possible lead plaintiff status. It's important to note that you don’t need to be a lead plaintiff to participate in any potential recovery.

What Are the Allegations?

The legal action involves claims that during the aforementioned class period, Neumora Therapeutics made misleading statements and omitted critical information concerning its clinical trial phases. Key allegations include:
1. Neumora allegedly altered the original trial criteria to register better results for its leading candidate, Navacaprant, intended for treating Major Depressive Disorder (MDD).
2. The amendments made to the Phase Two trials were criticized for lacking comprehensive data, especially regarding gender distribution in patient trials.
3. Consequently, there are concerns that these actions misled investors about Neumora's true potential and the effectiveness of their key therapeutic product.

Importance of Acting Promptly

As part of its information-gathering process, The Gross Law Firm will incorporate shareholders into portfolio monitoring systems post-registration for updates about the case. It's noteworthy that there is no cost or obligation tied to your participation, which should alleviate concerns about financial implications when seeking justice.

Executives from The Gross Law Firm emphasize that protecting the rights of investors is paramount. The firm is committed to holding companies accountable for poor business practices and misleading communications that cause financial harm to shareholders. Such initiatives are crucial in fostering accountability in the corporate sector, ensuring that companies maintain transparency and integrity in their operations.

How to Register

If you fall within the identified class of shareholders who purchased shares of Neumora Therapeutics, it's essential to act swiftly. For those interested, registration can occur through the law firm's official website, where you can submit the necessary information for enrollment.

Conclusion

The deadline for potential claims is approaching rapidly. If you are a shareholder of Neumora Therapeutics, don’t hesitate to reach out to The Gross Law Firm to learn about your options. Protecting your investments and rights as a shareholder can drive more responsible corporate behavior and safeguard your financial interests.

For further inquiries or to file your claim, you can contact: